Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
1.730
+0.030 (1.76%)
At close: Nov 13, 2026, 4:00 PM EST
1.760
+0.030 (1.73%)
After-hours: Nov 13, 2026, 7:30 PM EST

Voyager Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
25.1140.3780250.0140.9137.42
Revenue Growth
-19.82%-49.53%-68.00%511.16%9.33%-78.14%
Gross Profit
-79.46-91.9-44.59157.84-14.86-36.37
Operating Income
-109.52-128.34-80.51122.01-45.84-73.62
Net Income
-104.53-119.72-65132.33-46.41-71.2
Earnings Per Share
-1.74-2.04-1.132.97-1.21-1.89
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
132.13201.69332.39230.88118.85132.54
Total Debt
30.5136.543.7320.2923.1344.18
Net Cash (Debt)
101.63165.19288.66210.5895.7288.36
Net Cash Growth
-46.69%-42.77%37.08%119.99%8.33%-33.83%
Net Cash Per Share
1.692.815.014.722.502.35

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-109.19-132.47-15.3177.92-12.51-53.53
Capital Expenditures
-0.64-2.6-3.52-3.26-2.49-1.61
Free Cash Flow
-109.83-135.06-18.8374.66-15-55.13
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--227.62%-55.74%63.13%-36.32%-97.21%
Operating Margin
-436.18%-317.89%-100.64%48.80%-112.05%-196.76%
Pretax Margin
-416.08%-296.17%-80.42%53.49%-113.41%-190.29%
Profit Margin
-416.32%-296.53%-81.25%52.93%-113.45%-190.29%
FCF Margin
-437.43%-334.53%-23.54%29.86%-36.67%-147.36%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---2.81--
P/FCF Ratio
---4.97--
PS Ratio
4.295.413.871.495.762.75